Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
| (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -7.51%16.5B | -5.16%12.52B | -5.67%8.1B | -11.23%3.8B | 14.45%17.84B | 19.24%13.21B | 18.28%8.59B | 23.05%4.28B | -19.18%15.59B | -26.89%11.07B |
| Operating income | -7.51%16.5B | -5.16%12.52B | -5.67%8.1B | -11.23%3.8B | 14.45%17.84B | 19.24%13.21B | 18.28%8.59B | 23.05%4.28B | -19.18%15.59B | -26.89%11.07B |
| Cost of sales | 7.49%-15.22B | ---- | 5.41%-7.46B | ---- | -15.34%-16.45B | ---- | -19.55%-7.89B | ---- | 19.87%-14.27B | ---- |
| Operating expenses | 7.49%-15.22B | 5.41%-7.46B | -15.34%-16.45B | -19.55%-7.89B | 19.87%-14.27B | |||||
| Gross profit | -7.80%1.28B | -8.65%637.05M | 4.84%1.39B | 5.61%697.38M | -10.96%1.32B | |||||
| Selling expenses | 16.30%-268.18M | ---- | 17.07%-127.9M | ---- | 0.28%-320.4M | ---- | 14.39%-154.22M | ---- | 29.88%-321.29M | ---- |
| Administrative expenses | 4.59%-439.85M | ---- | 12.39%-212.34M | ---- | -2.67%-461.02M | ---- | -10.93%-242.37M | ---- | 23.09%-449.02M | ---- |
| Revaluation surplus | ---- | ---- | -72.01%2.13M | ---- | ---- | ---- | 5,286.52%7.6M | ---- | ---- | ---- |
| -Changes in the fair value of financial assets | ---- | ---- | -72.01%2.13M | ---- | ---- | ---- | 5,286.52%7.6M | ---- | ---- | ---- |
| Impairment and provision | -43.68%-33.93M | ---- | ---- | ---- | 53.93%-23.61M | ---- | ---- | ---- | -243.41%-51.25M | ---- |
| -Goodwill impairment | -1.73%-35.62M | ---- | ---- | ---- | 34.47%-35.01M | ---- | ---- | ---- | ---53.42M | ---- |
| -Other impairment is provision | -85.16%1.69M | ---- | ---- | ---- | 425.25%11.4M | ---- | ---- | ---- | -93.93%2.17M | ---- |
| Special items of operating profit | -81.23%25.55M | ---- | -58.45%26.32M | ---- | 49.08%136.11M | ---- | -52.15%63.33M | ---- | -61.01%91.3M | ---- |
| Operating profit | -21.70%561.64M | -12.50%325.25M | 21.16%717.3M | -5.70%371.71M | -16.95%592.03M | |||||
| Financing cost | 18.95%-307.99M | ---- | 18.18%-157.95M | ---- | 2.42%-380.02M | ---- | -0.68%-193.06M | ---- | -9.84%-389.44M | ---- |
| Share of profits of associates | 123.99%8.85M | ---- | 63.90%-8.65M | ---- | -178.86%-36.91M | ---- | 42.06%-23.97M | ---- | 156.37%46.8M | ---- |
| Earning before tax | -12.61%262.51M | 2.56%158.64M | 20.45%300.38M | -3.96%154.68M | -33.77%249.39M | |||||
| Tax | 22.52%-41.7M | ---- | -53.42%-41.11M | ---- | 39.50%-53.81M | ---- | 11.74%-26.8M | ---- | -55.06%-88.95M | ---- |
| After-tax profit from continuing operations | -10.44%220.81M | -8.10%117.53M | 53.68%246.57M | -2.15%127.88M | -49.74%160.44M | |||||
| Earning after tax | -10.44%220.81M | -8.10%117.53M | 53.68%246.57M | -2.15%127.88M | -49.74%160.44M | |||||
| Minority profit | 3.88%-53.37M | ---- | 49.95%-23.16M | ---- | 45.76%-55.52M | ---- | -25.44%-46.27M | ---- | -10,674.69%-102.36M | ---- |
| Profit attributable to shareholders | -9.24%274.18M | -19.22%140.69M | 14.95%302.09M | 3.92%174.15M | -17.42%262.8M | |||||
| Basic earnings per share | -6.59%0.0893 | -18.51%0.0449 | 15.04%0.0956 | 3.96%0.0551 | -14.94%0.0831 | |||||
| Diluted earnings per share | ||||||||||
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
| Auditor | Deloitte Touche Tohmatsu会计师事务所 | -- | -- | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | -- | -- | Deloitte Touche Tohmatsu会计师事务所 | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.